➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Dow
Moodys
Harvard Business School
Colorcon

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

LEMTRADA Drug Profile


Email this page to a colleague

« Back to Dashboard

Summary for Tradename: LEMTRADA
Patents:398
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for LEMTRADA
Recent Clinical Trials for LEMTRADA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Northwestern UniversityPhase 2
M.D. Anderson Cancer CenterPhase 1
National Cancer Institute (NCI)Phase 1

See all LEMTRADA clinical trials

Pharmacology for LEMTRADA

Company Disclosures: US Patents for LEMTRADA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Get Started Free Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Get Started Free Burroughs Wellcome Co. (Research Triangle Park, NC) 2013-08-13 RX Orphan company
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Get Started Free Burroughs Wellcome Co. (Research Triangle Park, NC) 2014-08-05 RX Orphan company
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Get Started Free British Technology Group Limited (London, GB) 2015-12-08 RX Orphan company
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Get Started Free Allergan, Inc. (Irvine, CA) 2013-12-28 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for LEMTRADA

These patents were identified by searching patent claims

Supplementary Protection Certificates for LEMTRADA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
PA2016019 Lithuania   Get Started Free PRODUCT NAME: ALEMTUZUMABAS; REGISTRATION NO/DATE: EU/1/13/869 20130912
122019000006 Germany   Get Started Free PRODUCT NAME: TISAGENLECLEUCEL; REGISTRATION NO/DATE: EU/1/18/1297 20180823
CA 2019 00007 Denmark   Get Started Free PRODUCT NAME: TISAGENLECLEUCEL; REG. NO/DATE: EU/1/18/1297 20180827
132016000055697 Italy   Get Started Free PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916
LUC00105 Luxembourg   Get Started Free PRODUCT NAME: KYMRIAH - TISAGENLECLEUCEL; AUTHORISATION NUMBER AND DATE: EU/1/18/1297 20180827
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Baxter
Merck
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.